Introduction {#jcmm13307-sec-0001}
============

Recent findings from studies in animal models and patients suggest that microbiota from human body may contribute to the development of various disorders, including diabetes, atherosclerosis and related cardiovascular disorders. Interestingly, trimethylamine N‐oxide (TMAO), an organic compound that was first found in marine organisms [1](#jcmm13307-bib-0001){ref-type="ref"}, [2](#jcmm13307-bib-0002){ref-type="ref"}, is recently proposed to be involved. Physiologically, TMAO functions by stabilizing proteins exposed to urea and pressure stress in deep sea creatures. In humans, choline‐, L‐carnitine‐ and lecithin‐derived mainly from red meat, egg yolks, dairy products and seafood can be hydrolysed by trimethylamine (TMA) lyase from gut flora to form the major depository of TMA in gastrointestinal tracts [3](#jcmm13307-bib-0003){ref-type="ref"}, [4](#jcmm13307-bib-0004){ref-type="ref"}. TMA is further oxygenated into TMAO by hepatic flavin monooxygenases (FMOs) in host liver, followed by kidney clearance or distribution to different tissues [5](#jcmm13307-bib-0005){ref-type="ref"}. A human mutation on FMO3 causes trimethylaminuria, a rare genetic defect with which patients fail to convert choline‐derived TMA into TMAO, resulting in a strong fishy odour from body excretions [6](#jcmm13307-bib-0006){ref-type="ref"}. So far, several strains of bacteria, including *Firmicutes*,*Proteobacteria*,*Anaerococcus hydrogenalis*,*Clostridium asparagiforme*,*C. hathewayi*,*C. sporogenes*,*Escherichia fergusonii*,*Proteus penneri*,*Providencia rettgeri*,*Edwardsiella tarda* and *Desulfovibrio desulfuricans*, have been identified as potential producers of TMAO *in vivo* [6](#jcmm13307-bib-0006){ref-type="ref"}. Recently, increased serum TMAO level is observed in patients with congestive heart failure and associated with an increased mortality in the same population [2](#jcmm13307-bib-0002){ref-type="ref"}, [7](#jcmm13307-bib-0007){ref-type="ref"}. Moreover, a positive association between plasma TMAO level and colorectal cancer has also been reported [8](#jcmm13307-bib-0008){ref-type="ref"}.

Cardiovascular diseases (CVD), including coronary artery disease, peripheral artery disease and cerebral vascular disease, are the leading cause of mortality worldwide, which contribute to over 30% of global mortality annually [9](#jcmm13307-bib-0009){ref-type="ref"}. A hallmark of CVD is atherosclerosis that is commonly associated with a broad spectrum of risk factors including hypertension, smoking, diabetes, hyperlipidaemia and ageing [10](#jcmm13307-bib-0010){ref-type="ref"}. It has been confirmed that influence of life style, such as the dietary pattern, may significantly affect the morbidity and prognosis of CVD patients. Generally, Mediterranean diet is related to decreased CVD risk, while excessive intake of carbohydrate and high‐fat diet substantially raises the incidence of CVD [11](#jcmm13307-bib-0011){ref-type="ref"}. Notably, effects of microbiota and changes of TMAO have been involved in the underlying mechanisms contributing to the association between dietary pattern and CVD risk. Indeed, an early prospective cohort study suggested that increased serum TMAO level independently predicts major adverse cardiovascular events (MACE) in over 4000 patients undergoing elective cardiac catheterization [12](#jcmm13307-bib-0012){ref-type="ref"}. Subsequent studies demonstrated that the pernicious aspects of TMAO in atherosclerosis may include the potential interactions with inflammatory pathways, cholesterol metabolism, platelet activation and subsequent thrombosis events [13](#jcmm13307-bib-0013){ref-type="ref"}. Although subsequent cohort studies in patients with coronary acute syndrome [14](#jcmm13307-bib-0014){ref-type="ref"} and chronic kidney disease (CKD) [15](#jcmm13307-bib-0015){ref-type="ref"}, [16](#jcmm13307-bib-0016){ref-type="ref"}, [17](#jcmm13307-bib-0017){ref-type="ref"}, [18](#jcmm13307-bib-0018){ref-type="ref"} further confirmed the prognostic role of circulating TMAO for CVD outcome, some studies failed to detect a significant association between TMAO level and CVD prognosis [19](#jcmm13307-bib-0019){ref-type="ref"}. Therefore, in this study, we performed a systematic review and meta‐analysis of all available cohort studies to quantitatively evaluate the association between baseline circulating TMAO and subsequent cardiovascular events.

Methods {#jcmm13307-sec-0002}
=======

Search strategy {#jcmm13307-sec-0003}
---------------

We searched the PubMed and Embase databases from the inception up to 15 January 2017 for relevant studies without language restriction. Methods used are in compliance with the PRISMA statement for reporting systematic reviews and the Meta‐analysis of Observational Studies in Epidemiology (MOOSE) guidelines [20](#jcmm13307-bib-0020){ref-type="ref"}. Supplement materials displays the PRISMA checklist. The search terms used were as follows: (((trimethylamine oxide) OR tmao)) AND ((((((((((cardiovascular disease) OR coronary heart disease) OR stroke) OR heart failure) OR myocardial infarction) OR ischaemic heart disease) OR sudden cardiac arrest) OR acute coronary syndrome) OR mortality) OR cardiovascular death). To identify additional eligible studies, we also screened the references of included papers and published meta‐analysis.

Selection criteria {#jcmm13307-sec-0004}
------------------

The inclusion criteria of the current systematic review and meta‐analysis were as follows: (1) studies conducted in human; (2) designed as a prospective cohort study; (3) plasma or serum trimethylamine N‐oxide level was evaluated at baseline; (4) major cardiovascular events (cardiovascular mortality, MI, cardiovascular hospitalization, revascularization and stroke) or all‐cause mortality were reported as the end‐points; (5) hazard ratios (HR) with confidence intervals (CI) were reported or could be estimated as for the association between baseline TMAO and CVEs. We excluded studies that are narrative reviews, animal experiments, case reports or present insufficient data for pooling. Studies without adjustments for confounding factor, including age, gender, eGFR, N‐proBNP or traditional CVD risk factors, were also excluded. The database searching and subsequent review of the literatures were performed *via* two independent reviewers. Consultation with a senior investigator was carried out with consensus to resolve any remaining discrepancies.

Data extraction {#jcmm13307-sec-0005}
---------------

Surname of the first author, country of origin, year of publication, sample size, research design, gender, age, follow‐up period, serum TMAO, disease outcome, adjustment variables, HRs (or ORs, RRs) with their corresponding 95% CIs were extracted for each potentially included study. Outcome assessed in the meta‐analysis included risk of CVD, all‐cause mortality and major adverse cardiac and cerebrovascular event (MACCE) including congestive heart failure (CHF), MI, death due to cardiac causes, stroke and cardiac transplantation. Two independent investigators extracted the data using a pre‐designed data extraction form. Divergences were resolved by consensus or consulting a senior investigator.

Quality evaluation {#jcmm13307-sec-0006}
------------------

Newcastle--Ottawa Scale [21](#jcmm13307-bib-0021){ref-type="ref"} was applied to evaluate the risk of bias for included studies based on study group selection, group comparability and ascertainment of exposure or outcome. We also assessed the quality of evidence in GRADE system by Grade Pro 4.04 (designed by Grade Working Group) and the results are displayed in Table [S2](#jcmm13307-sup-0001){ref-type="supplementary-material"}. Two reviewers independently assessed the quality of each study.

Statistical analysis {#jcmm13307-sec-0007}
--------------------

HRs and their corresponding Cis were used to evaluate the risk of cardiovascular outcome for patients with the highest quartile as compared with the lowest quartile of TMAO levels. The definitions of quartiles of baseline TMAO were in consistent with the original definition of the literatures. Heterogeneity among studies was evaluated using the Cochran\'s *Q* test and quantified using the *I* ^2^ static. Random‐effects model was applied for all meta‐analyses in spite of those with fewer than five studies, for which both fixed‐effect and random‐effects models were used to calculate pooled HRs. Fixed‐effect model was also used when heterogeneity was absent (*I* ^2^ = 0%). We explored potential sources of heterogeneity *via* subgroup analysis by study population, sample type, country of origin, follow‐up duration and year of publication. A meta‐regression model fitted with co‐variables including study population, sample type, country of origin, follow‐up duration and year of publication was analysed to explore potential sources of heterogeneity. In sensitivity analysis, the influence of each single study on overall estimates was evaluated. To assess the influence of new studies on overall effects, we performed cumulative meta‐analysis according to the year of publication for individual studies. Publication bias and selective reporting were examined by visual inspection of the asymmetry of funnel plot, in which the standard error of log HR was plotted against HR. Egger\'s and Begg\'s linear regression tests were conducted to determine statistical significance [22](#jcmm13307-bib-0022){ref-type="ref"}. The trim‐and‐fill approach was utilized to determine the number of additional studies required to overcome potential bias and provide adjusted effects. All statistical analyses were performed with STATA software, version 14.1 (StataCorp LP, College Station, TX, USA). A two‐sided *P* value \<0.05 was considered with statistical significance.

Results {#jcmm13307-sec-0008}
=======

Literature search {#jcmm13307-sec-0009}
-----------------

Totally, 400 records from Embase and PubMed databases were retrieved. After removing 160 duplicates, the remaining 240 records were further examination for the titles and abstracts. Among these papers, 207 are not associated with the theme and six are not prospective studies. Full‐text review further excluded 16 articles, yielding a sum of 11 studies for the meta‐analysis.

Of these studies, five presented odds ratio (OR) [14](#jcmm13307-bib-0014){ref-type="ref"}, [23](#jcmm13307-bib-0023){ref-type="ref"}, [24](#jcmm13307-bib-0024){ref-type="ref"}, [25](#jcmm13307-bib-0025){ref-type="ref"}, [26](#jcmm13307-bib-0026){ref-type="ref"} rather than hazard ratio; two did not present 95% CI [19](#jcmm13307-bib-0019){ref-type="ref"}, [27](#jcmm13307-bib-0027){ref-type="ref"}; one defined onset of chronic kidney disease as the primary outcome [28](#jcmm13307-bib-0028){ref-type="ref"}; two reported outcome by per S.D. increment of TMAO [16](#jcmm13307-bib-0016){ref-type="ref"}, [19](#jcmm13307-bib-0019){ref-type="ref"}. The studying subjects in six studies conducted by a same group were those who underwent diagnostic coronary angiography (CAG) [4](#jcmm13307-bib-0004){ref-type="ref"}, [12](#jcmm13307-bib-0012){ref-type="ref"}, [29](#jcmm13307-bib-0029){ref-type="ref"}, [30](#jcmm13307-bib-0030){ref-type="ref"}, [31](#jcmm13307-bib-0031){ref-type="ref"}, [32](#jcmm13307-bib-0032){ref-type="ref"}. Of them, five later studies, which enroled patients with heart failure (HF), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), PAD and stable CAD, were extended subgroup follow‐ups from the first large cohort with overlaps in studying population and were thus not considered for pooling outcome in our meta‐analysis [4](#jcmm13307-bib-0004){ref-type="ref"}, [29](#jcmm13307-bib-0029){ref-type="ref"}, [30](#jcmm13307-bib-0030){ref-type="ref"}, [31](#jcmm13307-bib-0031){ref-type="ref"}, [32](#jcmm13307-bib-0032){ref-type="ref"}. Comprehensive full‐text reviewing eventually yielded 11 eligible studies for pooling in the meta‐analysis [12](#jcmm13307-bib-0012){ref-type="ref"}, [28](#jcmm13307-bib-0028){ref-type="ref"}, [33](#jcmm13307-bib-0033){ref-type="ref"}, [34](#jcmm13307-bib-0034){ref-type="ref"}, [35](#jcmm13307-bib-0035){ref-type="ref"}, [36](#jcmm13307-bib-0036){ref-type="ref"}, [37](#jcmm13307-bib-0037){ref-type="ref"}, [38](#jcmm13307-bib-0038){ref-type="ref"}, [39](#jcmm13307-bib-0039){ref-type="ref"}, [40](#jcmm13307-bib-0040){ref-type="ref"}, [41](#jcmm13307-bib-0041){ref-type="ref"}. A flow chart describing the process of study selection is presented in Figure [1](#jcmm13307-fig-0001){ref-type="fig"}.

![Flow chart of study selection.](JCMM-22-185-g001){#jcmm13307-fig-0001}

Study characteristics {#jcmm13307-sec-0010}
---------------------

The detailed characteristics of the 11 prospective studies published from 2013 to 2017 are shown in Table [1](#jcmm13307-tbl-0001){ref-type="table-wrap"}. Among these studies, three were conducted in the United States [12](#jcmm13307-bib-0012){ref-type="ref"}, [39](#jcmm13307-bib-0039){ref-type="ref"}, [40](#jcmm13307-bib-0040){ref-type="ref"}, while others were performed in New Zealand [41](#jcmm13307-bib-0041){ref-type="ref"}, Canada [37](#jcmm13307-bib-0037){ref-type="ref"}, Germany [36](#jcmm13307-bib-0036){ref-type="ref"}, Sweden [28](#jcmm13307-bib-0028){ref-type="ref"}, England [33](#jcmm13307-bib-0033){ref-type="ref"}, [34](#jcmm13307-bib-0034){ref-type="ref"} and Norway [35](#jcmm13307-bib-0035){ref-type="ref"}, [38](#jcmm13307-bib-0038){ref-type="ref"}, respectively. Follow‐up durations of these studies ranged from 0.5 to 6.1 years. Patients undergoing elective coronary angiography (CAG) [12](#jcmm13307-bib-0012){ref-type="ref"}, patients with coronary artery disease (CAD) [33](#jcmm13307-bib-0033){ref-type="ref"}, [35](#jcmm13307-bib-0035){ref-type="ref"}, [41](#jcmm13307-bib-0041){ref-type="ref"}, patients with HF [34](#jcmm13307-bib-0034){ref-type="ref"}, [38](#jcmm13307-bib-0038){ref-type="ref"}, [39](#jcmm13307-bib-0039){ref-type="ref"} and patients with CKD [28](#jcmm13307-bib-0028){ref-type="ref"}, [37](#jcmm13307-bib-0037){ref-type="ref"}, [40](#jcmm13307-bib-0040){ref-type="ref"} were included. A study presented outcome for CAP patients with or without comorbidity of CAD [36](#jcmm13307-bib-0036){ref-type="ref"}, and this study was treated as two cohorts. Generally, the size of study cohorts varied from 112 to 4007 participants, with a total of 10,245 subjects included in the final meta‐analysis. Outcome reported from these studies was overall mortality and cardiovascular events including myocardial infarction, coronary revascularization, stroke, cardiovascular hospitalization and mortality. Two of the included studies presented TMAO levels for patients with events and without events, respectively [12](#jcmm13307-bib-0012){ref-type="ref"}, [36](#jcmm13307-bib-0036){ref-type="ref"}. All included studies were of moderate‐to‐high quality, as indicated by individual NOS scores ranging from 5 to 8.

###### 

Characteristics of included prospective cohort studies

  Author            Year   Country       Population                  Scale           Follow‐up years   Subjects   Male (%)   Age           Assay   Sample   Design   TMAO level                    Outcome         Quality score   Quality of evidence
  ----------------- ------ ------------- --------------------------- --------------- ----------------- ---------- ---------- ------------- ------- -------- -------- ----------------------------- --------------- --------------- ---------------------
  Tang, W. H.       2013   USA           GP                          Single‐centre   3                 4007       64         63 ± 11       LCMS    Plasma   PCS      \<2.43 *versus* \>6.18 μM     CVEs or Death   8               High
  Lever, M.         2014   New Zealand   CAD and CAD plus diabetes   Single‐centre   5                 396        73         68 (55--93)   LCMS    Plasma   PCS      \<2.8 *versus* \>12.0 μM      CVEs or Death   5               Low
  Kaysen, G. A.     2015   USA           CKD                         Multi‐centre    5                 235        55         61.8 ± 14.2   LCMS    Serum    PCS      \<27.5 *versus* \>66.6 μM     CVEs or Death   5               Low
  Tang, W. H.       2015   USA           HF                          Multi‐centre    5                 112        74         57 ± 14       LCMS    Plasma   PCS      \<15 *versus* \>15 μM         Death           8               High
  Troseid, M.       2015   Norway        HF                          Single‐centre   0.5               155        83         57 ± 11       LCMS    Plasma   PCS      \<9.23 *versus* \>9.23 μM     Death           6               Moderate
  Kim, R. B.        2015   Canada        CKD                         Multi‐centre    3                 2529       63         68.2 ± 12.7   LCMS    Plasma   PCS      \<20.41 *versus* \>20.41 μM   CVEs            5               Moderate
  Ottiger, M.       2016   German        CAP and CAP plus CAD        Multi‐centre    6.1               317        59         72 (57--82)   LCMS    Plasma   PCS      \<2.3 *versus* \>4.1 μM       Death           5               Low
  Skagen, K.        2016   Norway        CAD                         Single‐centre   1                 264        69         67.6 ± 8.4    LCMS    Serum    PCS      \<9.77 *versus* \>9.77 μM     Death           7               High
  Missailidis, C.   2016   Sweden        CKD                         Single‐centre   3                 179        65         55 ± 14       LCMS    Plasma   PCS      \<32.2 *versus* \>72.2 μM     Death           6               Moderate
  Suzuki, T.        2016   England       HF                          Single‐centre   1                 972        61         78 (69--84)   LCMS    Plasma   PCS      \<5.6 *versus* \>5.6 μM       Death           5               Moderate
  Suzuki, T.        2017   England       CAD                         Single‐centre   2                 1079       72         65 (57--77)   LCMS    Plasma   PCS      \<2.9 *versus* \>5.1 μM       CVEs or Death   5               Moderate

HF: heart failure; CKD: chronic kidney disease; CAD: coronary artery disease; PCS: prospective cohort study.
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TMAO and CVEs {#jcmm13307-sec-0011}
-------------

Five prospective cohorts with a total of 8139 participants reported HRs for the association between baseline TMAO and CVEs risk [12](#jcmm13307-bib-0012){ref-type="ref"}, [33](#jcmm13307-bib-0033){ref-type="ref"}, [37](#jcmm13307-bib-0037){ref-type="ref"}, [40](#jcmm13307-bib-0040){ref-type="ref"}, [41](#jcmm13307-bib-0041){ref-type="ref"}. Pooled results indicated that increased TMAO level was independently associated with increased risk for CVEs (HR 1.23, 95% CI: 1.07--1.42). The heterogeneity among the included studies was mild (*I* ^2^ = 31.4%, *P* = 0.212; Fig. [2](#jcmm13307-fig-0002){ref-type="fig"}). No significant publication bias was detected with the visual inspection of the funnel plot (Figure [S1](#jcmm13307-sup-0001){ref-type="supplementary-material"}) or the results of Egger\'s (*P* = 0.497) and Begg\'s tests (*P* = 0.806).

![Forest plot (random‐effects model) for the association between baseline TMAO (highest *versus* lowest category) and CVD events or Death.](JCMM-22-185-g002){#jcmm13307-fig-0002}

TMAO and all‐cause mortality {#jcmm13307-sec-0012}
----------------------------

Ten out of 11 included studies, which included 7716 participants, reported the potential association between baseline TMAO and risk of all‐cause mortality [12](#jcmm13307-bib-0012){ref-type="ref"}, [28](#jcmm13307-bib-0028){ref-type="ref"}, [33](#jcmm13307-bib-0033){ref-type="ref"}, [34](#jcmm13307-bib-0034){ref-type="ref"}, [35](#jcmm13307-bib-0035){ref-type="ref"}, [36](#jcmm13307-bib-0036){ref-type="ref"}, [38](#jcmm13307-bib-0038){ref-type="ref"}, [39](#jcmm13307-bib-0039){ref-type="ref"}, [40](#jcmm13307-bib-0040){ref-type="ref"}, [41](#jcmm13307-bib-0041){ref-type="ref"}. Meta‐analysis demonstrated that elevated TMAO levels were independently associated with increased mortality risk (HR 1.55, 95% CI: 1.19--2.02). However, a considerable heterogeneity was noticed among different studies (*I* ^2^ = 80.8%, *P* \< 0.001) (Fig. [2](#jcmm13307-fig-0002){ref-type="fig"}). Subsequently, we performed subgroup analysis to evaluate the potential effects of study population, sample type, country of origin, follow‐up years and time of publication on the association between baseline TMAO and mortality risk. We found that higher TMAO levels were associated with a 61% (HR = 1.61, 95% CI: 1.15--2.26, *I* ^2^ = 66.7%) increase of overall mortality in CAD patients, but not in patients with CKD or HF (CKD: HR = 1.99, 95% CI: 0.55--7.20, *I* ^2^ = 75.2%; HF: HR = 1.21, 95% CI: 0.93--1.57, *I* ^2^ = 60.4%; Figure [S2](#jcmm13307-sup-0001){ref-type="supplementary-material"}). For the latter two subgroups, fixed‐effect model was used to estimate pooled HRs (USA: HR = 1.95, 95% CI: 1.57--2.42; CKD: HR = 1.53, 95% CI: 1.21--1.94). Furthermore, pooled HR from studies performed in the United States (HR = 1.80, 95% CI: 0.94--3.46) was not statistically significant while those in other countries showed a 41% higher risk of death in patients with increased TMAO levels (HR = 1.41, 95% CI: 1.09--1.82, *I* ^2^ = 68.8%). In addition, elevated TMAO was associated with increased mortality risk in studies with plasma samples (HR = 1.63, 95% CI: 1.19--1.23, *I* ^2^ = 84.5%), but not in studies with serum samples (HR = 1.28, 95% CI: 0.93--1.78, *I* ^2^ = 0%). Additional subgroup analyses showed similar increases of mortality risk in studies with different follow‐up periods (follow‐up \<5 years: HR = 1.59, 95% CI: 1.09--2.33, *I* ^2^ = 87.8%; follow‐up \>5 years: HR = 1.53, 95% CI: 1.07--2.19, *I* ^2^ = 56.9%). As all included studies in this meta‐analysis have been published within 5 years, we checked whether the year of publication affected the pooled HR by cumulative analysis (Figure [S3](#jcmm13307-sup-0001){ref-type="supplementary-material"}a, [3](#jcmm13307-sup-0001){ref-type="supplementary-material"}b). The association of baseline TMAO and mortality risk remained after the addition of more recent studies, which was further confirmed by the results of meta‐regression for publication year (*P* = 0.285). Fitting other variables, including country of origin, follow‐up years, sample types and population, into the meta‐regression model did not indicate additional sources of heterogeneity (Table [2](#jcmm13307-tbl-0002){ref-type="table-wrap"}). Results of sensitivity analysis did not support a certain study impacting the overall outcome significantly (Figure [S4](#jcmm13307-sup-0001){ref-type="supplementary-material"}a, [4](#jcmm13307-sup-0001){ref-type="supplementary-material"}b). According to the results, no individual study was found responsible for the observed heterogeneity.

###### 

Stratified analyses of pooled hazard risks of TMAO and CVD events

  Stratified analysis   Number of studies   Pooled HR (95% CI)   Heterogeneity                               Meta‐regression (*P* value)
  --------------------- ------------------- -------------------- ------------------------------------------- -----------------------------
  Country                                                                                                    0.503
  USA                   3                   1.80 (0.94--3.46)    *Q* = 16.85, *P* = 0.000, *I* ^2^ = 88.1%   
  Non‐USA               8                   1.41 (1.09--1.82)    *Q* = 22.45, *P* = 0.002, *I* ^2^ = 68.8%   
  Follow‐up years                                                                                            0.858
  \<5 years             6                   1.59 (1.09--2.33)    *Q* = 41.14, *P* = 0.000, *I* ^2^ = 87.8%   
  ≥5 years              5                   1.53 (1.07--2.19)    *Q* = 9.28, *P* = 0.054, *I* ^2^ = 56.9%    
  Public year                                                                                                0.285
  Before 2015           6                   1.83 (1.20--2.78)    *Q* = 22.10, *P* = 0.000, *I* ^2^ = 81.9%   
  After 2015            5                   1.36 (0.89--2.06)    *Q* = 13.62, *P* = 0.009, *I* ^2^ = 70.6%   
  Population                                                                                                 0.213
  HF                    3                   1.28 (1.11--1.47)    *Q* = 0.80, *P* = 0.670, *I* ^2^ = 0%       
  CAD                   5                   1.47 (1.06--2.02)    *Q* = 10.71, *P* = 0.030 *I* ^2^ = 62.6%    
  CKD                   4                   1.58 (1.13--2.19)    *Q* = 4.82, *P* = 0.186 *I* ^2^ = 37.7%     
  Samples                                                                                                    0.535
  Plasma                9                   1.63 (1.19--2.23)    *Q* = 51.63, *P* = 0.000, *I* ^2^ = 84.5%   
  Serum                 2                   1.28 (0.93--1.78)    *Q* = 0.31, *P* = 0.577, *I* ^2^ = 0%       
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The funnel plot showed obvious asymmetry, indicating the presence of publication bias (Fig. [3](#jcmm13307-fig-0003){ref-type="fig"}). Application of trim‐and‐fill model suggested that three more studies may be required to eliminate the publication bias, although the pooled effect was markedly different (HR = 1.23, 95% CI: 0.90--1.67) (Fig. [4](#jcmm13307-fig-0004){ref-type="fig"}A and B). Nonetheless, statistics using the Egger\'s (*P* = 0.436) and Begg\'s (*P* = 0217) regression tests did not show significant bias in publication (Figure [S5](#jcmm13307-sup-0001){ref-type="supplementary-material"}). We also use the standard 'Risk of bias' tool and Newcastle‐Ottawa Scale (NOS) to evaluate bias (Figure [S6](#jcmm13307-sup-0001){ref-type="supplementary-material"}a, [S6](#jcmm13307-sup-0001){ref-type="supplementary-material"}b; Tables [1](#jcmm13307-tbl-0001){ref-type="table-wrap"} and [S3](#jcmm13307-sup-0001){ref-type="supplementary-material"}).

![Funnel plot for the association between baseline TMAO (highest *versus* lowest category) and CVD events or Death.](JCMM-22-185-g003){#jcmm13307-fig-0003}

![Meta trim‐and‐fill model (**A**) and filled funnel plot (**B**).](JCMM-22-185-g004){#jcmm13307-fig-0004}

Discussion {#jcmm13307-sec-0013}
==========

In this study, by pooling the data from 11 available prospective cohort studies incorporating 10,245 participants, we found that higher circulating TMAO at baseline was independently associated with 23% increment risk of subsequent CVEs and 55% increment of all‐cause mortality. Although significant heterogeneity was detected for the association of baseline TMAO and risk of all‐cause mortality, subsequent subgroup and meta‐analyses did not support that the characteristics of included patients, follow‐up duration, location of the study and sample of TMAO had significant effects on the association between TMAO and CVEs or mortality risks. These results suggest that participants with higher baseline TMAO were at higher risk of future cardiovascular risk. Future studies are needed to determine whether circulating TMAO confers prognostic efficacy for CVDs.

Intake of foods such as eggs, beef and fish is known to raise the blood and urine concentrations of TMAO [7](#jcmm13307-bib-0007){ref-type="ref"}, [42](#jcmm13307-bib-0042){ref-type="ref"}. Increased TMAO has been demonstrated to promote insulin resistance and adipose inflammation in mice and associated with increased risk of developing type 2 diabetes mellitus in human [29](#jcmm13307-bib-0029){ref-type="ref"}. More recently, TMAO has been suggested as a candidate of proatherogenic molecules in circulation due to its detrimental metabolic effects and contribution in foam cell formation [21](#jcmm13307-bib-0021){ref-type="ref"}. In addition, the interference of bile acid metabolism and sterol transportation has also been shown to underlie the pernicious roles of TMAO in the development of atherosclerosis [7](#jcmm13307-bib-0007){ref-type="ref"}. As mentioned previously, a pilot study suggests the potential predictive role of circulating TMAO as risk of CVEs in patients undergoing elective coronary angiography [12](#jcmm13307-bib-0012){ref-type="ref"}. Subsequently, higher high‐TMAO level was linked to adverse clinical outcome in patients with HF, CKD and T2DM, respectively [29](#jcmm13307-bib-0029){ref-type="ref"}, [32](#jcmm13307-bib-0032){ref-type="ref"}, [39](#jcmm13307-bib-0039){ref-type="ref"}. Subsequent analyses were not always supportive of the predictive role of TMAO.

Nevertheless, the results on the link between TMAO and CVD remain limited and inconsistent. For instance, TMAO exhibited no significant predictive value on CVEs and mortality in a 4‐year observational cohort including 235 patients with CKD [40](#jcmm13307-bib-0040){ref-type="ref"}. Similar result was obtained from a more recent U.K. study in patients with HF [19](#jcmm13307-bib-0019){ref-type="ref"}. Two studies from Norway enrolling patients with CAD and HF also failed to show any evident correlation between TMAO and risk of death [38](#jcmm13307-bib-0038){ref-type="ref"}, [43](#jcmm13307-bib-0043){ref-type="ref"}. In another German study recruiting patients with comorbidities of community‐acquired pneumonia and CAD, higher TMAO level did not sufficiently predict an increase in mortality rate [36](#jcmm13307-bib-0036){ref-type="ref"}. More intriguingly, consumption of seafood that is rich in TMAO has been found to confer significant protection against cardiovascular disease rather than predisposing to deleterious outcome. To the best of our knowledge, ours is the first systematic review and meta‐analysis exploring the prognostic value of TMAO in CVEs and mortality has been published so far. Results of our study further confirmed that higher TMAO at baseline was associated with increased risk of CVEs and all‐cause mortality. Moreover, our subsequent subgroup analyses found that the vast disagreement among studies may attribute to various aspects, including patient population (CKD, HF, T2DM and CAD), race (Black and White) and sample type (serum and plasma). Spectacularly, only studies conducted outside the United States exhibited a significant overall HR for the high‐TMAO effect on mortality. In spite, studies published after the year 2015 did not suggest a positive correlation between increased TMAO and higher risk of death. This finding is consistent with our cumulative analysis that showed a progressive reduction in the pooled HR with the addition of more recent studies. This discrepancy may be resulted from different followed‐up durations. However, this was not supported by our meta‐regression for publication time and follow‐up duration. Of note, pooled HRs of mortality was substantially different between studies using plasma and those testing serum samples. This finding was supported by the significant difference between baseline TMAO levels in plasma and serum indicated in a methodology study. However, the result remains uncertain given limited number of studies in the serum group, and further studies with larger sample size are needed to confirm our results.

The mechanisms underlying the potential association between TMAO and risks of cardiovascular diseases deserve further investigation. Some previously published experimental studies may provide some clues. TMAO may increase platelet activity through the potentiation of cytoplasmic calcium release, by which it may predispose to a hyper‐coagulating status and increased thrombotic events [13](#jcmm13307-bib-0013){ref-type="ref"}. Additional mechanisms by which TMAO regulates cardiovascular health may involve the prolongation of angiotensin effects, which is also likely to exacerbate cardiac remodelling and contributes to detrimental outcome in heart failure [44](#jcmm13307-bib-0044){ref-type="ref"}. TMAO is also known to play a role in the perturbation of metabolic networks in type 2 diabetes, in which a synergistic effect by increased TMAO on the prognosis has been reported [29](#jcmm13307-bib-0029){ref-type="ref"}. In patients with compromised renal function, attenuated clearance of TMAO may results in an elevation of circulating TMAO. Subsequently increased TMAO can induce kidney fibrosis *via* activation of the TGF‐β‐Smad3 pathway [4](#jcmm13307-bib-0004){ref-type="ref"}. In addition, increased risk of having cancer may also be additive to poor prognosis in those with elevated TMAO levels [45](#jcmm13307-bib-0045){ref-type="ref"}. As kidney is the major organ responsible for the clearance of circulating TMAO in human, a drastic elevation of serum TMAO has been readily seen in those with renal failure. Consistently, plasma TMAO level was found to be negatively related the eGFR. Uraemic patient had the highest TMAO level, which can be dramatically reduced by haemodialysis. This may possible explain the very high heterogeneity observed in patients with CKD [28](#jcmm13307-bib-0028){ref-type="ref"}. Furthermore, studies that adjusted for more comprehensive CVD risk factors tend to show positive prognostic effects on mortality by TMAO [12](#jcmm13307-bib-0012){ref-type="ref"}, indicating these factors as underlying sources of inter‐study heterogeneity.

Strength and limitations {#jcmm13307-sec-0014}
------------------------

Our study demonstrated potential prognostic power of TMAO in a variety of populations. To our knowledge, this is the first meta‐analysis that shows a positive correlation between high‐TMAO level and adverse cardiovascular outcome. In this study, we included only prospective cohorts and followed the PRISMA and MOOSE guidelines. Potential sources of heterogeneity were explored using different methods, and trim‐and‐fill strategy was applied to solve the possibility of publication bias. All of the above aspects added to the power of the study. Our study also has potential limitations, which should be considered when interpreting the results. Firstly, studies that did not provide sufficient data for pooling were excluded from the meta‐analysis [14](#jcmm13307-bib-0014){ref-type="ref"}, [23](#jcmm13307-bib-0023){ref-type="ref"}, [24](#jcmm13307-bib-0024){ref-type="ref"}, [25](#jcmm13307-bib-0025){ref-type="ref"}, [26](#jcmm13307-bib-0026){ref-type="ref"}, which may raise risk of bias in the overall effects by TMAO. Considerable risk of publication bias was identified for the association between high TMAO and all‐cause mortality, leading to a dubitative conclusion of the link. Moreover, considerable heterogeneities existed in baseline clinical characteristics including age, gender and race across individual studies. Additionally, uncontrolled cofounding factors including dietary patterns and genetic variation may significantly affect the concentration of TMAO. Inclusion of those studies without comprehensive adjustment may yield inaccurate effects. Moreover, the lack of continuous data made it difficult to draw a quantitative result on the difference of TMAO between subjects with and without events. Finally, results of our meta‐analysis of observational studies could only provide the potential temporal association between increased circulating TMAO and subsequent CVD risk. Whether increased TMAO was causative to poor cardiovascular outcome deserves further investigation.

Conclusion {#jcmm13307-sec-0015}
==========

Participants with higher baseline TMAO were at higher risk for future cardiovascular risk. Further large‐scale prospective cohorts or even interventional studies are warranted to evaluate the diagnostic power of TMAO and its causative role on cardiovascular outcome.
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